Tag: Nicox
Nicox: 9.1 million in cash, visibility until November 2024 – 04/22/2024 at 09:43
(AOF) – Nicox announces a cash position of 9.1 million euros as of March 31, 2024: its cash horizon extends until November 2024. The international company specializing in ophthalmology specifies…
Nicox: Cash of 9.1 million euros at the end of March
Read also (CercleFinance.com) – Nicox announced on Monday that it had 9.1 million euros in cash as of March 31, compared to 11.9 million at the end of 2023, which…
Nicox: cash of 9.1 million euros at the end of March – 04/22/2024 at 10:40 a.m.
(CercleFinance.com) – Nicox announced on Monday that it had 9.1 million euros in cash as of March 31, compared to 11.9 million at the end of 2023, which allows it…
Nicox plans to secure funding to support the clinical development of NCX 470
By Arnaud Bivès Published on 03/13/2024 at 08:40 a.m. (Boursier.com) — Nicox whose resources are focused on…
Nicox is focusing its strengths on the development of its NCX 470 product
(AOF) – Nicox announces that its resources are focused on the clinical development of its main program, NCX 470, against glaucoma. The biotech specializing in ophthalmology is counting on obtaining…
Nicox restructures its debt to extend its cash horizon
By Arnaud Bivès Published on 02/28/2024 at 7:51 a.m. (Boursier.com) — Nicox signed an agreement in principle…
Nicox: restructures its debt, visibility extended until November 2024
(AOF) – Nicox announces that it is restructuring its debt and reducing its structure to extend its cash horizon and prioritize resources on the pivotal study on NCX 470. The…
Nicox: License agreement with Kowa for the development and marketing of the NCX 470 in Japan
By Hector Chaunu Published on 02/08/2024 at 08:09 a.m. (Boursier.com) — Nicox SA, an international company specializing in…
Nicox obtains extension of the American patent on Vyzulta – 01/31/2024 at 10:08
(AOF) – Nicox announced that the United States Patent and Trademark Office (USPTO) has decided that the American patent covering latanoprostene bunod marketed by Bausch + Lomb under the brand…
Nicox had cash of €11.9 million as of December 31
(Boursier.com) — Nicox SA, an international company specializing in ophthalmology, today presents a financial summary and the main activities of Nicox SA and its subsidiaries for the fourth quarter of…
Nicox: turnover up 29% in 2023
(CercleFinance.com) – Nicox announced on Friday that royalties collected from Vyzulta, its ophthalmic solution licensed to Bausch + Lomb, had exceeded the threshold of four million euros for the first…
Nicox: Potential annual worldwide net sales of the NCX 470 estimated at more than $300 million
(Boursier.com) — Nicox SA Announces Market Research in the United States to Assess the Commercial Potential of NCX 470, a Nitric Oxide (NO)-Donating Bimatoprost, in Development for the Reduction of…